From: The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer
 | Cx43 | Cx26 | Cx32 | Cx46 | Ki67 | |||||
---|---|---|---|---|---|---|---|---|---|---|
 | pre | post | pre | post | pre | post | pre | post | pre | post |
ER pre | 0.30 | x | ns | x | ns | x | ns | x | −0.46 | −0.35 |
ER post | 0.36 | ns | ns | ns | ns | ns | ns | ns | −0.40 | −0.38 |
PR pre | 0.34 | x | ns | x | ns | x | ns | x | −0.45 | x |
PR post | 0.33 | ns | ns | ns | ns | ns | ns | ns | −0.52 | ns |
HER2 pre | −0.27 | x | ns | x | 0.31 | x | ns | x | ns | x |
HER2 post | ns | ns | ns | ns | ns | ns | ns | ns | ns | 0.26 |
cT pre | 0.29 | x | ns | x | ns | x | ns | x | ns | x |
cN pre | ns | x | ns | x | ns | x | ns | x | ns | x |
pT post | ns | ns | ns | ns | −0.29 | ns | ns | ns | ns | ns |
pN post | ns | ns | ns | ns | ns | ns | 0.39 | 0.32 | ns | ns |
grade pre | ns | x | ns | x | ns | x | ns | x | ns | ns |
Ki67 pre | ns | x | ns | x | ns | x | −0.29 | x | x | 0.46 |
Ki67 post | ns | ns | ns | ns | ns | 0.46 | ns | ns | 0.46 | x |